Home/Pipeline/Autoimmune psoriasis candidate

Autoimmune psoriasis candidate

Psoriasis

PreclinicalActive

Key Facts

Indication

Psoriasis

Phase

Preclinical

Status

Active

Company

Australian‑listed biotech advancing TRPC‑channel inhibitors for cardiovascular and neurological unmet needs.

Drug	Company	Phase	Status
CYPS317	FibroBiologics	Discovery	Active
PEP Biologic™	Intent Biologics	Unknown	Active
DMT410	Dermata Therapeutics	Preclinical	Exploratory
IL23R program	Acellera	Pre-clinical	Hit-to-Lead
Undisclosed Psoriasis Program	Nepsone	Preclinical	Active
TEM-1657 (Topical)	Temisis	Pre-clinical	Active
TEM-1657 (Oral)	Temisis	Pre-clinical	Active
AIM Platform	Phaim Pharma	Pre-clinical	Active
orismilast	UNION therapeutics	Phase 2	Active
Laikangqita Monoclonal Antibody	Livzon Pharmaceutical	NDA	Marketing application accepted and granted priority review
CT-P55	Celltrion	Phase 3	Active
JNJ-77242113	Johnson & Johnson	Phase 3	Active